Novel Drug Delivery Systems Market by Route of Administration (Injectable Drug Delivery Systems, Oral Drug Delivery Systems, Pulmonary Drug Delivery Systems), Mode (Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, Targeted Drug Delivery

Novel Drug Delivery Systems Market by Route of Administration (Injectable Drug Delivery Systems, Oral Drug Delivery Systems, Pulmonary Drug Delivery Systems), Mode (Controlled Drug Delivery Systems, Modulated Drug Delivery Systems, Targeted Drug Delivery Systems), End-User - Global Forecast 2024-2030

The Novel Drug Delivery Systems Market size was estimated at USD 13.83 billion in 2023 and expected to reach USD 15.00 billion in 2024, at a CAGR 9.17% to reach USD 25.57 billion by 2030.

Novel drug delivery systems (NDDS) refer to the advanced methods and technologies used in pharmaceuticals to formulate medicines that can be delivered to the body in non-traditional ways. The market for novel drug delivery systems encompasses diverse technologies and methodologies designed to transport pharmaceutical compounds to specific parts of the body to enhance efficacy, control drug release, and improve patient compliance. The prevalence of chronic diseases, a significant rise in the geriatric population, and advancements in controlled drug release technologies are influencing the growth of the novel drug delivery systems market. Government approvals for novel drug delivery systems are accelerating the market's growth. Existing limitations associated with novel drug delivery systems, complications, and expertise required in delivering therapeutics and drugs may limit scalability and widespread usage. Ongoing advancements in developing novel drug delivery systems and the rising adoption of self-injectable devices are expected to provide growth opportunities in the market.

Regional Insights

The novel drug delivery systems (NDDS) market in the Americas is driven by robust technological advancements and significant investments in research and development, with a strong focus on personalized medicine. The presence of key pharmaceutical companies and a well-established healthcare infrastructure contribute to the pioneering position of this region. The regulatory framework facilitated by the FDA in the United States sets a conducive environment for introducing and adopting innovative drug delivery solutions. South America's market for NDDS is emerging with growing awareness and increasing healthcare expenditure. Europe has the highest adoption of NDDS, backed by strong governmental support and high-quality healthcare systems. In contrast, the Middle East and Africa are also adapting to the advancements owing to increasing strategic partnerships and investments in healthcare sectors. The Asia-Pacific region is witnessing significant growth in the NDDS market attributed to growing economies and increasing healthcare investments. Due to their technological capabilities and substantial healthcare spending, China and Japan are major countries. Additionally, the growing pharmaceutical sectors in India and Southeast Asia are contributing significantly to the expansion of the NDDS market.

Market Insights

• Market Dynamics
  
  The market dynamics represent an ever-changing landscape of the Novel Drug Delivery Systems Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
  • Market Drivers
    • Prevalence of Chronic Diseases and Significant Rise in Geriatric Population
    • Advancements in Controlled Drug Release Technologies
    • Government Approvals for Novel Drug Delivery Systems
    • Market Restraints
      • Existing Limitations Associated with Novel Drug Delivery System
      • Market Opportunities
        • Ongoing Advancements for Development of Novel Drug Delivery Systems
        • Rising Adoption of Self-Injectable Devices
        • Market Challenges
          • Complications and Expertise Required in Delivering Therapeutics and Drugs
          • Market Segmentation Analysis
            • Route of Administration: Rising adoption of injectable drug delivery systems for chronic disease management
            • End-User: Increasing use of novel drug delivery systems in the hospital due to budget constraints and the necessity to cater to a larger patient base
            • Market Disruption Analysis
            • Porter’s Five Forces Analysis
            • Value Chain & Critical Path Analysis
            • Pricing Analysis
            • Technology Analysis
            • Patent Analysis
            • Trade Analysis
            • Regulatory Framework Analysis
            FPNV Positioning Matrix
            
            The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Novel Drug Delivery Systems Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
            
            Market Share Analysis
            
            The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Novel Drug Delivery Systems Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
            
            Recent Developments
            • Novel drug delivery one-stop shop
              
              The Intracellular Drug Delivery Centre, a collaboration involving Medicines Discovery Catapult, the University of Strathclyde, the University of Liverpool, and Imperial College London, has been established to advance novel drug delivery technologies, particularly for RNA vaccines and therapeutics. Funded by a GBP 10 million grant from Innovate UK's Transforming Medicines Manufacturing programme, this groundbreaking UK-first partnership fosters integrated access to groundbreaking lipid nanoparticle (LNP) formulations and spearhead the development of next-generation nano delivery systems.
              
              Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
              
              Viridian Therapeutics, Inc. announced its strategic collaboration with Enable Injections. This collaboration, excluding Viridian's Thyroid Eye Disease (TED) catalog, underlines the firm's resolve to bridge the gap between medical discoveries and patient accessibility, fortifying a legacy of impactful patient care.
              
              Kindeva Drug Delivery acquires Summit Biosciences
              
              Kindeva Drug Delivery acquired Summit Biosciences to bolster its position in the CDMO market. Integrating Summit's capabilities is expected to enrich Kindeva's portfolio with advanced nasal drug delivery solutions, aligning with the shift towards non-invasive administration methods that favor patient convenience and care.
            Strategy Analysis & Recommendation
            
            The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Novel Drug Delivery Systems Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
            
            Key Company Profiles
            
            The report delves into recent significant developments in the Novel Drug Delivery Systems Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca Plc, Bayer AG, Boston Scientific Corporation, Bristol Myers Squibb Company, Cospheric LLC, Enable Injections, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Insulet Corporation, Johnson & Johnson Services, Inc., Lonza Group Ltd., Merck KGaA, Merit Medical Systems, Inc., Mo-Sci Corporation, Novartis AG, Pacira BioSciences, Inc., Pfizer Inc., Polysciences Inc., Sanofi S.A., Societal CDMO, Spectrum Pharmaceuticals, Inc., Terumo Medical Corporation, Thermo Fisher Scientific Inc., and West Pharmaceutical Services, Inc..
            
            Market Segmentation & Coverage
            
            This research report categorizes the Novel Drug Delivery Systems Market to forecast the revenues and analyze trends in each of the following sub-markets:
            • Route of Administration
              • Injectable Drug Delivery Systems
              • Oral Drug Delivery Systems
              • Pulmonary Drug Delivery Systems
              • Transdermal Drug Delivery Systems
              • Mode
                • Controlled Drug Delivery Systems
                • Modulated Drug Delivery Systems
                • Targeted Drug Delivery Systems
                • End-User
                  • Hospital
                  • Research Centers
                  • Specialty Clinics
                  • Region
                    • Americas
                      • Argentina
                      • Brazil
                      • Canada
                      • Mexico
                      • United States
                        • California
                        • Florida
                        • Illinois
                        • New York
                        • Ohio
                        • Pennsylvania
                        • Texas
                        • Asia-Pacific
                          • Australia
                          • China
                          • India
                          • Indonesia
                          • Japan
                          • Malaysia
                          • Philippines
                          • Singapore
                          • South Korea
                          • Taiwan
                          • Thailand
                          • Vietnam
                          • Europe, Middle East & Africa
                            • Denmark
                            • Egypt
                            • Finland
                            • France
                            • Germany
                            • Israel
                            • Italy
                            • Netherlands
                            • Nigeria
                            • Norway
                            • Poland
                            • Qatar
                            • Russia
                            • Saudi Arabia
                            • South Africa
                            • Spain
                            • Sweden
                            • Switzerland
                            • Turkey
                            • United Arab Emirates
                            • United Kingdom
                            
                            
                            Please Note: PDF & Excel + Online Access - 1 Year